MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that Ivan Dimov, Ph.D., Orca Bio’s chief executive officer and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference.
The company presentation will take place virtually on Tuesday, January 11, 2022, at 6:30 AM PST (9:30 AM EST).
About Orca Bio
Orca Bio is a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than standard allogeneic stem cell transplants, like graft versus host disease and other debilitating transplant-related toxicities. At Orca Bio, we hope to not only replace patients’ blood and immune systems with healthy ones, but restore their quality of life. For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @orcabio.
Contacts
Investor Relations
Joshua Murray
ir@orcabio.com
Corporate Communications
Kelsey Grossman
media@orcabio.com